Ubs Group Ag T Scan Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 19,344 shares of TCRX stock, worth $59,579. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,344

Previous 12,645 52.98%

Holding current value

$59,579

Previous $73,000 31.51%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.97 - $7.49 $33,294 - $50,175	6,699 Added 52.98%	19,344 $96,000
Q2 2024 Aug 13, 2024	BUY	$5.85 - $9.51 $62,852 - $102,175	10,744 Added 565.18%	12,645 $73,000
Q1 2024 May 13, 2024	BUY	$4.89 - $8.3 $2,332 - $3,959	477 Added 33.5%	1,901 $15,000
Q4 2023 Feb 09, 2024	BUY	$2.66 - $6.76 $821 - $2,088	309 Added 27.71%	1,424 $8,000
Q3 2023 Nov 09, 2023	BUY	$2.04 - $2.94 $30 - $44	15 Added 1.36%	1,115 $2,000
Q2 2023 Aug 11, 2023	SELL	$1.64 - $4.85 $3,509 - $10,379	-2,140 Reduced 66.05%	1,100 $2,000
Q1 2023 May 12, 2023	BUY	$1.66 - $3.32 $3,718 - $7,436	2,240 Added 224.0%	3,240 $6,000
Q4 2022 Feb 08, 2023	SELL	$1.49 - $3.33 $3,637 - $8,128	-2,441 Reduced 70.94%	1,000 $1,000
Q3 2022 Nov 10, 2022	BUY	$2.62 - $4.39 $6,007 - $10,066	2,293 Added 199.74%	3,441 $11,000
Q2 2022 Aug 10, 2022	BUY	$1.65 - $3.58 $1,894 - $4,109	1,148 New	1,148 $4,000
Q1 2022 May 16, 2022	SELL	$2.8 - $5.4 $2,270 - $4,379	-811 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$4.5 - $9.05 $607 - $1,221	-135 Reduced 14.27%	811 $4,000
Q3 2021 Nov 15, 2021	BUY	$6.17 - $13.48 $5,836 - $12,752	946 New	946 $8,000

Others Institutions Holding TCRX

# of Institutions

Shares Held

41.8M

Call Options Held

Put Options Held

View Full List

About TScan Therapeutics, Inc.

Ticker TCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,929,800
Market Cap $58.3M
Description
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...

More about TCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account